Lansforsakringar Fondforvaltning AB publ Acquires 42,803 Shares of Kenvue Inc. $KVUE

Lansforsakringar Fondforvaltning AB publ raised its holdings in Kenvue Inc. (NYSE:KVUE) by 7.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 630,410 shares of the company’s stock after buying an additional 42,803 shares during the quarter. Lansforsakringar Fondforvaltning AB publ’s holdings in Kenvue were worth $10,868,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in KVUE. Elyxium Wealth LLC bought a new position in shares of Kenvue during the fourth quarter valued at approximately $26,000. Physician Wealth Advisors Inc. increased its position in Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the period. MV Capital Management Inc. purchased a new position in Kenvue during the 4th quarter valued at $28,000. Reflection Asset Management bought a new position in Kenvue in the 4th quarter worth $32,000. Finally, SBI Securities Co. Ltd. lifted its position in shares of Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after purchasing an additional 1,027 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of KVUE stock opened at $19.33 on Thursday. The company’s fifty day moving average price is $17.76 and its 200-day moving average price is $17.68. The stock has a market cap of $37.11 billion, a PE ratio of 22.74, a price-to-earnings-growth ratio of 1.45 and a beta of 0.54. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $22.87.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. During the same period last year, the business earned $0.24 EPS. Kenvue’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities analysts expect that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.3%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on KVUE shares. Barclays cut their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Citigroup cut their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Finally, Argus raised Kenvue to a “hold” rating in a research report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $19.33.

Insider Buying and Selling at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.59% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.